Evaluating the neuroprotective activities of vinpocetine, punicalagin, niacin and vitamin E against behavioural and motor disabilities of manganese-induced Parkinson's disease in Sprague Dawley rats

• Published in: Biomedicine & pharmacotherapy Vol. 153; p. 113330
• Main Authors: Abu-Elfotuh, Karema, Hamdan, Ahmed Mohsen Elsaid, Abbas, Ashwaq Najemaldeen, Alahmre, Abdulelah Turki S., Elewa, Mohammed A.F., Masoud, Rehab Ali Elsayed, Ali, Azza A., Othman, Mohamed, Kamal, Mona M., Hassan, Fatma Alzahraa M., Khalil, Mona G., El-Sisi, Ahmed M., Abdel Hady, Manal M.M., Abd-Elhaleim El Azazy, Marwa Khaled, Awny, Magdy M., Wahid, Ahmed
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-09-2022; Elsevier
• Subjects: Acetylcholinesterase; Animals; Anti-Inflammatory Agents - pharmacology; Antioxidants - pharmacology; Antioxidants - therapeutic use; Glycogen Synthase Kinase 3 beta; Hydrolyzable Tannins; Manganese - pharmacology; Neuroprotection; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Niacin; Niacin - pharmacology; Oxidative Stress; Parkinson Disease - drug therapy; Parkinson’s disease; Punicalagin; Rats; Rats, Sprague-Dawley; Vinca Alkaloids; Vinpocetine; Vitamin E; Vitamin E - pharmacology; Oxidative stress; Punicalagin; Vitamin E; Niacin; Parkinson’s disease; Vinpocetine
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2022.113330

The current study investigated the neuroprotective activity of some drugs and nutriceuticals with antioxidant and anti-inflammatory potential on the pathogenesis of Parkinson’s disease (PD). Rats were categorized into seven groups: Rats received tween80 daily for 5 weeks as a control group, MnCl2 (10 mg/kg, i.p) either alone (group II) or in combination with vinpocetine (VIN) (20 mg/kg) (group III), punicalagin (PUN) (30 mg/kg) (group IV), niacin (85 mg/kg) (group V), vitamin E (Vit E) (100 mg/kg) (group VI) or their combination (group VII). Motor activities was examined using open-field and catalepsy. Striatal monamines, acetylcholinesterase, excitatory/inhibitory neurotransmitters, redox status, pro-oxidant content, brain inflammatory, apoptotic and antioxidant biomarkers levels were assessed. Besides, histopathological investigations of different brain regions were determined. Groups (IV –GVII) showed improved motor functions of PD rats. Applied drugs significantly increased the brain levels of monoamines with the strongest effect to PUN. Meanwhile, they significantly decreased levels of acetylcholinesterase with a strongest effect to PUN. Moreover, they exhibited significant neuronal protection and anti-inflammatory abilities through significant reduction of the brain levels of COX2, TNF-α and Il-1β with a strongest effect to the PUN. Interestingly; groups (IV – GVII) showed restored glutamate/GABA balance and exhibited a pronounced decrease in caspase-3 content and GSK-3β protein expression levels. In addition, they significantly increased Bcl2 mRNA expression levels with a strongest effect for PUN. All these findings were further confirmed by the histopathological examinations. As a conclusion, we propose VIN and PUN to mitigate the progression of PD via their antioxidant, anti-inflammatory, anti-apoptotic, neurotrophic and neurogenic activities.
[Display omitted]
•MnCl2 induces biochemical changes in the brain: reduction of monoamines and disturbing the imbalance between excitatory and inhibitory neurotransmitters.•MnCl2 changes the redox status and the inflammatory biomarkers of the brain tissues.•Punicalagin has maximum protective against decreased BDNF, monoamines, antioxidant contents levels and increased level of pro-oxidant content, brain cytokines, inflammatory and apoptotic markers.•Vinpocetine has maximum protective against decreased AChE, GABA and antioxidant contents and Bcl2 levels and increased level of glutamate.